The Efficacy of Combination of Traditional Tibetan and Remote Ischemic Conditioning on High Altitude Polycythemia

Capital Medical University

Status and phase: Not yet enrolling; Phase 3; Phase 2

Conditions: High Altitude Polycythemia

Treatments: Device: Remote Ischemic Conditioning; Drug: Tibetan Medicine (Shiliu Jianwei Powder, Ershiwuwei Yuganzi Pills, Qiwei Tiexue Pill)

Study type: Interventional

Funder types: Other

Identifiers

NCT06082583

HAPC

Details and patient eligibility

About

A multicenter, randomized controlled trial was designed to evaluate the effectiveness and safety of the comprehensive traditional Tibetan medicine program combined with remote ischemic conditioning on high altitude polycythemia.

Enrollment: 300 estimated patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with high-altitude polycythemia aging 18 to 65 years.

Exclusion criteria

• Allergic to Tibetan medicine ingredients;
• Inappropriate to receive Tibetan medicine treatment and/or remote ischemic conditioning.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

300 participants in 2 patient groups

Tibetan Medicine Group

Active Comparator group

Treatment:

Drug: Tibetan Medicine (Shiliu Jianwei Powder, Ershiwuwei Yuganzi Pills, Qiwei Tiexue Pill)

Tibetan Medicine-Remote Ischemic Conditioning Group

Experimental group

Treatment:

Drug: Tibetan Medicine (Shiliu Jianwei Powder, Ershiwuwei Yuganzi Pills, Qiwei Tiexue Pill)

Device: Remote Ischemic Conditioning